Farxiga
E505482
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Farxiga canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248763 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Farxiga Context triple: [AstraZeneca, notableProduct, Farxiga]
-
A.
Januvia
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Farxiga Target entity description: Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
A.
Januvia
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
SGLT2 inhibitor
ⓘ
antihyperglycemic agent ⓘ brand name drug ⓘ prescription medication ⓘ |
| approvalYear | 2014 ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | A10BK01 ⓘ |
| combinationTherapy |
may be used with insulin
ⓘ
may be used with metformin ⓘ may be used with other oral antidiabetic agents ⓘ |
| contraindication | patients with a history of serious hypersensitivity to dapagliflozin ⓘ |
| developer | AstraZeneca NERFINISHED ⓘ |
| doesNotTreat | type 1 diabetes mellitus ⓘ |
| dosageForm | tablet ⓘ |
| effect |
induces osmotic diuresis
ⓘ
lowers blood glucose levels ⓘ may reduce body weight ⓘ may reduce systolic blood pressure ⓘ |
| FDAApprovalStatus | approved ⓘ |
| hasActiveIngredient | dapagliflozin ⓘ |
| indication |
improve glycemic control in adults with type 2 diabetes
ⓘ
reduce risk of cardiovascular death and hospitalization for heart failure in adults with heart failure ⓘ reduce risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors ⓘ reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease ⓘ treatment of chronic kidney disease in adults ⓘ |
| lactationUse | caution advised ⓘ |
| marketingAuthorizationHolder | AstraZeneca NERFINISHED ⓘ |
| mechanismOfAction |
increases urinary glucose excretion
ⓘ
inhibits SGLT2 in the proximal renal tubules ⓘ reduces reabsorption of filtered glucose in the kidney ⓘ |
| monitoringParameter |
blood glucose
ⓘ
renal function ⓘ signs and symptoms of ketoacidosis ⓘ volume status ⓘ |
| pharmacologicClass | sodium-glucose cotransporter 2 inhibitor ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| risk |
acute kidney injury
ⓘ
genital mycotic infections ⓘ hypotension ⓘ ketoacidosis ⓘ urinary tract infections ⓘ volume depletion ⓘ |
| routeOfAdministration | oral ⓘ |
| takenWithOrWithoutFood | true ⓘ |
| treats | type 2 diabetes mellitus ⓘ |
| typicalDose |
10 mg once daily
ⓘ
5 mg once daily ⓘ |
| warning | not recommended in patients with severe renal impairment, end-stage renal disease, or on dialysis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Farxiga Description of subject: Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.